Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2013

View Archived Issues

Volasertib inferior to pemetrexed in phase II trial for NSCLC

Farletuzumab misses phase II endpoint for NSCLC

Small-molecule antagonists identified for the treatment of light-sensitive migraine

Isis Pharmaceuticals begins phase II trial of ISIS-GCCRRx in combination with metformin

RINT1 gene mutations linked to early-onset breast cancer

Phase I data for the GS-4774 vaccine confirm tolerability and immunogenicity

Otsuka and Lundbeck partner for nalmefene in Japan

CRT Pioneer Fund and Chroma form collaboration to develop anticancer drugs targeting macrophages

Mochida Pharmaceutical synthesizes novel FFA1 agonists

Fidelity Biosciences and ReGenX Biosciences launch new company

Achillion details development of hepatitis C virus candidate ACH-3422

New gamma-carbolines designed at IntraCellular Therapies

Chinese and U.S. team patents novel HD6 inhibitors

arGEN-X and de Duve Institute/UCL sign collaboration to develop immunomodulation therapy for cancer

Testing supports development of Pluristem's PLX cells for pre-eclampsia

Pfizer provides overview of third quarter 2013

Dainippon Sumitomo Pharma provides overview of second quarter of fiscal 2013

BioLineRx receives approval to begin trial of BL-7010 in celiac disease

Ampio Pharmaceuticals reports data from extension of SPRING study

Allegro Ophthalmics begins phase II study of ALG-1001 for vitreomacular traction

New IL-17 production inhibitors disclosed by Mitsubishi Tanabe Pharma

Almirall submits MAA in Europe for fixed-dose aclidinium and formoterol

LC-540449 demonstrates efficacy in a preclinical model of non-alcoholic steatohepatitis

Genkyotex begins multinational phase II study of NOX inhibitor

Actelion launches Opsumit for treatment of PAH in the U.S.

Thomson Reuters and NuMedii collaborate on drug repurposing initiative

AB Science to advance masitinib to phase III development for treatment of ALS

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...